← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

C4 Therapeutics, Inc. (CCCC) 10-Year Financial Performance & Capital Metrics

CCCC •
HealthcareBiotechnologyDrug Discovery and Antibody Platforms
AboutC4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Show more
  • Revenue $0 -100.0%
  • EBITDA -$115M +2.2%
  • Net Income -$105M +0.3%
  • EPS (Diluted) -1.27 +16.4%
  • Gross Margin -
  • EBITDA Margin -
  • Operating Margin -
  • Net Margin -
  • ROE -44.44% +2.5%
  • ROIC -36.91% +14.3%
  • Debt/Equity 0.23 -23.2%
  • Interest Coverage -
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Momentum leader: RS Rating 83 (top 17%)
  • ✓Trading at only 0.9x book value

✗Weaknesses

  • ✗Weak Piotroski F-Score: 3/9
  • ✗Shares diluted 19.5% in last year
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y-
3Y-
TTM-100%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM0.31%

EPS CAGR

10Y-
5Y-
3Y-
TTM15.89%

ROCE

10Y Avg-29.84%
5Y Avg-32.73%
3Y Avg-37.55%
Latest-36.55%

Peer Comparison

Drug Discovery and Antibody Platforms
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
REGNRegeneron Pharmaceuticals, Inc.107.56B781.6718.840.99%31.41%14.41%3.79%0.09
CTMXCytomX Therapeutics, Inc.430.14M5.3714.1336.45%24.66%26.09%
PRTCPureTech Health plc405.3M16.778.3944.98%-495.91%-8.53%0.05
DNAGinkgo Bioworks Holdings, Inc.327.53M6.75-1.20-25.06%-183.81%-61.5%0.82
BCYCBicycle Therapeutics plc111.38M5.73-1.9830.76%-8.85%-40.53%0.01
CCCCC4 Therapeutics, Inc.261.67M2.70-2.13-100%-40.92%0.23
MOLNMolecular Partners AG187.84M5.02-2.43-29.38%-10.87%-63.06%0.02
RXRXRecursion Pharmaceuticals, Inc.1.94B3.67-2.5526.92%-8.65%-57.01%0.07

Compare CCCC vs Peers

Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.

vs REGN

Compare head-to-head with Regeneron Pharmaceuticals, Inc.

vs CNTA

Compare head-to-head with Centessa Pharmaceuticals plc

Compare Top 5

vs REGN, CNTA, IMNM, CLDX

Profit & Loss

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Sales/Revenue+19.36M21.38M33.2M45.78M31.1M20.76M35.58M0
Revenue Growth %-10.42%55.25%37.93%-32.08%-33.25%71.44%-100%
Cost of Goods Sold+28.59M078.44M007.74M00
COGS % of Revenue147.66%-236.3%--37.28%--
Gross Profit+-9.23M21.38M-45.24M45.78M31.1M13.02M35.58M0
Gross Margin %-47.66%100%-136.3%100%100%62.72%100%-
Gross Profit Growth %-331.7%-311.61%201.19%-32.08%-58.13%173.32%-100%
Operating Expenses+35.75M56.83M15.2M127.92M160.63M152.05M155.2M151.17M
OpEx % of Revenue184.64%265.81%45.8%279.39%516.56%732.56%436.15%-
Selling, General & Admin7.16M8.77M15.2M33.25M42.79M42.08M42.12M36.2M
SG&A % of Revenue36.98%41.04%45.8%72.63%137.6%202.74%118.38%-
Research & Development28.59M48.06M78.44M94.67M117.84M117.71M110.64M104.24M
R&D % of Revenue147.66%224.77%236.3%206.76%378.96%567.09%310.92%-
Other Operating Expenses-7K0-78.44M00-7.74M2.44M10.73M
Operating Income+-16.39M-35.45M-60.45M-82.13M-129.53M-139.03M-119.61M-115.22M
Operating Margin %-84.64%-165.81%-182.1%-179.39%-416.56%-669.84%-336.15%-
Operating Income Growth %--116.32%-70.51%-35.87%-57.71%-7.33%13.97%3.67%
EBITDA+-12.82M-33.86M-58.83M-80.64M-127.86M-131.29M-117.8M-115.22M
EBITDA Margin %-66.18%-158.35%-177.23%-176.13%-411.17%-632.56%-331.04%-
EBITDA Growth %--164.18%-73.77%-37.07%-58.55%-2.69%10.28%2.19%
D&A (Non-Cash Add-back)3.57M1.59M1.62M1.49M1.68M7.74M1.82M0
EBIT-16.39M-33.3M-60.45M-81.75M-125.96M-129.84M-105.19M0
Net Interest Income+685K1.83M-836K-1.76M1.36M8.44M14.43M0
Interest Income685K1.83M393K387K3.58M9.81M14.43M0
Interest Expense001.23M2.15M2.22M1.37M00
Other Income/Expense678K2.16M-5.26M-1.76M1.36M7.82M14.43M10.35M
Pretax Income+-15.71M-33.3M-65.71M-83.89M-128.18M-131.21M-105.19M-104.87M
Pretax Margin %-81.14%-155.72%-197.95%-183.23%-412.19%-632.17%-295.6%-
Income Tax+0804K626K001.28M131K-121K
Effective Tax Rate %100%102.41%100.95%100%100%100.98%100.12%100.12%
Net Income+-15.71M-34.1M-66.33M-83.89M-128.18M-132.49M-105.32M-104.99M
Net Margin %-81.14%-159.48%-199.83%-183.23%-412.19%-638.34%-295.96%-
Net Income Growth %--117.04%-94.54%-26.47%-52.79%-3.37%20.51%0.31%
Net Income (Continuing)-15.71M-34.1M-66.33M-83.89M-128.18M-132.49M-105.32M-104.99M
Discontinued Operations00000000
Minority Interest00000000
EPS (Diluted)+-1.06-0.79-1.54-1.82-2.62-2.67-1.52-1.27
EPS Growth %-25.47%-94.94%-18.18%-43.96%-1.91%43.07%16.45%
EPS (Basic)-1.06-0.79-1.54-1.82-2.62-2.67-1.52-1.27
Diluted Shares Outstanding42.09M42.99M43.06M46.04M48.86M49.64M69.37M82.89M
Basic Shares Outstanding14.79M42.99M43.06M46.04M48.86M49.64M69.37M82.89M
Dividend Payout Ratio--------

Balance Sheet

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Current Assets+123.53M96.77M381.01M325.69M287.56M271.19M257.77M258.11M
Cash & Short-Term Investments36.31M90.55M371.69M309.28M276.15M253.68M244.9M248.54M
Cash Only36.31M90.55M181.73M76.12M29.75M126.59M55.5M74.6M
Short-Term Investments00189.96M233.16M246.4M127.09M189.41M173.93M
Accounts Receivable86.44M4.62M4.48M5.72M1.47M11.8M3.1M2.4M
Days Sales Outstanding1.63K78.9249.345.5717.29207.4931.82-
Inventory0000-60.96M000
Days Inventory Outstanding--------
Other Current Assets000070.89M5.71M9.76M7.17M
Total Non-Current Assets+22.96M21.49M19.13M181.08M143.28M105.26M91.83M100.97M
Property, Plant & Equipment20.38M18.92M16.55M35.05M77.52M71.09M63.38M45.28M
Fixed Asset Turnover0.95x1.13x2.01x1.31x0.40x0.29x0.56x-
Goodwill00000000
Intangible Assets00000000
Long-Term Investments2.58M00142.2M60.96M28.01M22.36M0
Other Non-Current Assets02.58M2.58M3.82M4.8M6.17M6.1M55.69M
Total Assets+146.49M118.26M400.14M506.76M430.84M376.45M349.6M359.07M
Asset Turnover0.13x0.18x0.08x0.09x0.07x0.06x0.10x-
Asset Growth %--19.27%238.35%26.65%-14.98%-12.62%-7.13%2.71%
Total Current Liabilities+23.95M33.64M43.85M51.25M44.55M42.77M45.18M33.03M
Accounts Payable1.15M5.38M5.68M4.51M1.17M1.45M1.33M858K
Days Payables Outstanding14.73-26.44--68.22--
Short-Term Debt00002.29M006.37M
Deferred Revenue (Current)19.11M20.7M27.6M31.8M16.62M15.47M18.71M12.49M
Other Current Liabilities1.26M3.33M4.19M5.5M3.11M9.39M9.3M14.17M
Current Ratio5.16x2.88x8.69x6.36x6.46x6.34x5.71x7.81x
Quick Ratio5.16x2.88x8.69x6.36x7.82x6.34x5.71x7.81x
Cash Conversion Cycle--------
Total Non-Current Liabilities+202.29M196.58M75.5M65.91M97.06M87.57M88.44M69.46M
Long-Term Debt0010.05M10.77M9.2M0053.62M
Capital Lease Obligations13.75M12.87M11.83M30.78M70.97M65.76M59.98M0
Deferred Tax Liabilities-13.75M0000000
Other Non-Current Liabilities111M111M0000015.84M
Total Liabilities226.24M230.22M119.35M117.16M141.61M130.34M133.62M102.49M
Total Debt+14.48M13.75M22.92M42.88M87.15M70.98M65.76M59.98M
Net Debt-21.83M-76.8M-158.81M-33.24M57.4M-55.61M10.26M-14.62M
Debt / Equity--0.08x0.11x0.30x0.29x0.30x0.23x
Debt / EBITDA--------
Net Debt / EBITDA--------
Interest Coverage---49.19x-38.29x-58.45x-101.26x--
Total Equity+-79.75M-111.96M280.79M389.61M289.23M246.11M215.99M256.59M
Equity Growth %--40.39%350.79%38.75%-25.76%-14.91%-12.24%18.8%
Book Value per Share-1.89-2.606.528.465.924.963.113.10
Total Shareholders' Equity-79.75M-111.96M280.79M389.61M289.23M246.11M215.99M256.59M
Common Stock1K04K5K5K6K7K9K
Retained Earnings-83.39M-117.49M-183.82M-267.71M-395.89M-528.38M-633.7M-738.69M
Treasury Stock-6.14M0000000
Accumulated OCI-2.5M013K-775K-4.14M-127K53K50K
Minority Interest00000000

Cash Flow

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Cash from Operations+-16.98M55.61M-67.25M-86.97M-105.94M-106.84M-65.16M-98.69M
Operating CF Margin %-87.69%260.11%-202.59%-189.94%-340.68%-514.73%-183.11%-
Operating CF Growth %-427.51%-220.92%-29.32%-21.82%-0.85%39.01%-51.47%
Net Income-15.71M-34.1M-66.33M-83.89M-128.18M-132.49M-105.32M-104.99M
Depreciation & Amortization1.27M1.59M1.62M1.49M1.68M1.88M1.82M1.96M
Stock-Based Compensation582K1.64M3.43M21.51M30.02M27.23M29.66M19.1M
Deferred Taxes66K350K5.58M1.88M0000
Other Non-Cash Items2.37M1.14M1.63M2.13M7.32M3.48M1.03M-14.76M
Working Capital Changes-5.56M84.98M-13.18M-30.09M-16.78M-6.94M7.65M0
Change in Receivables-84.94M81.81M139K-1.23M4.24M-10.33M8.7M701K
Change in Inventory-2.22M2.17M-1.58M-2.63M0000
Change in Payables578K4.23M467K-1.18M-3.33M273K-119K-468K
Cash from Investing+36.92M-1.62M-190.5M-189.34M58.42M158.35M-51.27M-8.6M
Capital Expenditures-2.69M-1.35M-650K-1.28M-5.5M-1.71M-180K-607K
CapEx % of Revenue13.89%6.31%1.96%2.79%17.67%8.23%0.51%-
Acquisitions063K189.85M188.06M-63.92M000
Investments--------
Other Investing39.61M0-189.85M-188.06M63.92M000
Cash from Financing+1.96M244K348.93M171.4M1.15M45.49M45.34M126.4M
Debt Issued (Net)0011.97M00-12.5M00
Equity Issued (Net)1000K-30K1000K1000K777K1000K1000K0
Dividends Paid00000000
Share Repurchases-63K-30K-194K00-110K-194K-193K
Other Financing-63K274K-3.45M1.94M370K426K1.16M126.4M
Net Change in Cash21.9M54.24M91.18M-104.9M-46.37M97M-71.09M19.1M
Free Cash Flow+-19.67M54.27M-67.9M-88.24M-111.44M-108.55M-65.34M-99.3M
FCF Margin %-101.58%253.8%-204.55%-192.73%-358.36%-522.96%-183.61%-
FCF Growth %-375.88%-225.12%-29.96%-26.28%2.59%39.81%-51.98%
FCF per Share-0.471.26-1.58-1.92-2.28-2.19-0.94-1.20
FCF Conversion (FCF/Net Income)1.08x-1.63x1.01x1.04x0.83x0.81x0.62x0.94x
Interest Paid00820K00990K00
Taxes Paid01.09M143K001M00

Key Ratios

Metric20182019202020212022202320242025
Return on Equity (ROE)---78.58%-25.03%-37.76%-49.5%-45.58%-44.44%
Return on Invested Capital (ROIC)---37.17%-25.76%-27.64%-38.83%-43.05%-36.91%
Gross Margin-47.66%100%-136.3%100%100%62.72%100%-
Net Margin-81.14%-159.48%-199.83%-183.23%-412.19%-638.34%-295.96%-
Debt / Equity--0.08x0.11x0.30x0.29x0.30x0.23x
Interest Coverage---49.19x-38.29x-58.45x-101.26x--
FCF Conversion1.08x-1.63x1.01x1.04x0.83x0.81x0.62x0.94x
Revenue Growth-10.42%55.25%37.93%-32.08%-33.25%71.44%-100%

Deep Dive Analysis

Explore detailed financial history, valuation models, and returns analysis

Valuation Overview

DCF models, peer multiples & analyst estimates

Total Return Calculator

Historical returns with dividends reinvested

Dividend History

Yield, growth, payout safety & DRIP calculator

Earnings History

EPS trends, net income & profitability analysis

Price History

Long-term charts & historical price data

Revenue History

Sales growth patterns & revenue breakdown

Financial Ratios

30 years of valuation, profitability & efficiency metrics

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.